Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 501 extension in rheumatoid arthritis
NCT02114931Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of adalimumab in rheumatoid arthritis (RA), sponsored by Amgen. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02114931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114931.